First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

Overview of attention for article published in Journal of Hematology & Oncology, March 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 53 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 47 followers.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitum... https://t.co/afRGZtXj6s

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.